NYSE: BAK
Braskem Sa Stock Forecast, Predictions & Price Target

Analyst price target for BAK

Based on 1 analyst offering 12 month price targets for Braskem Sa

Min Forecast
$5.00+46.63%
Avg Forecast
$5.00+46.63%
Max Forecast
$5.00+46.63%

Should I buy or sell BAK stock?

Based on 1 analyst offering ratings for Braskem Sa.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BAK stock forecasts and price targets.

BAK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-27

1 of 1

Forecast return on equity

Is BAK forecast to generate an efficient return?

Company
-66.26%
Industry
4.56%
Market
-19.67%
BAK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BAK forecast to generate an efficient return on assets?

Company
3.12%
Industry
2.35%
BAK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BAK earnings per share forecast

What is BAK's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.16
Avg 2 year Forecast
$0.00
Avg 3 year Forecast
$0.69

BAK revenue forecast

What is BAK's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$13.8B+10.15%
Avg 2 year Forecast
$15.4B+22.55%
Avg 3 year Forecast
$15.5B+24.12%
BAK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BAK revenue growth forecast

How is BAK forecast to perform vs Chemicals companies and vs the US market?

Company
5.52%
Industry
2.43%
Market
11.9%
BAK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BAK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BAK vs Chemical Stocks

TickerPricePrice TargetUp/downsideConsensus
BAK$3.41$5.00+46.63%Hold
REX$30.46$25.00-17.93%Strong Buy
HUN$10.90$11.96+9.68%Hold
ASPI$8.97$11.00+22.63%Strong Buy
TROX$4.95$5.01+1.27%Buy

Braskem Sa Stock Forecast FAQ

Is Braskem Sa Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: BAK) stock is to Hold BAK stock.

Out of 1 analyst, 0 (0%) are recommending BAK as a Strong Buy, 0 (0%) are recommending BAK as a Buy, 1 (100%) are recommending BAK as a Hold, 0 (0%) are recommending BAK as a Sell, and 0 (0%) are recommending BAK as a Strong Sell.

If you're new to stock investing, here's how to buy Braskem Sa stock.

What is BAK's earnings growth forecast for 2025-2027?

(NYSE: BAK) Braskem Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Chemicals industry's average forecast earnings growth rate of 0.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.31%.

Braskem Sa's earnings in 2025 is -$1,965,277,777.On average, 2 Wall Street analysts forecast BAK's earnings for 2025 to be -$123,567,214, with the lowest BAK earnings forecast at -$183,357,802, and the highest BAK earnings forecast at -$63,776,627. On average, 2 Wall Street analysts forecast BAK's earnings for 2026 to be $0, with the lowest BAK earnings forecast at -$199,301,959, and the highest BAK earnings forecast at $199,301,959.

In 2027, BAK is forecast to generate $550,073,405 in earnings, with the lowest earnings forecast at $550,073,405 and the highest earnings forecast at $550,073,405.

What is BAK's revenue growth forecast for 2025-2027?

(NYSE: BAK) Braskem Sa's forecast annual revenue growth rate of 5.52% is forecast to beat the US Chemicals industry's average forecast revenue growth rate of 2.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.

Braskem Sa's revenue in 2025 is $13,439,409,722.On average, 2 Wall Street analysts forecast BAK's revenue for 2025 to be $10,999,479,075,654, with the lowest BAK revenue forecast at $10,721,153,890,609, and the highest BAK revenue forecast at $11,277,804,260,699. On average, 2 Wall Street analysts forecast BAK's revenue for 2026 to be $12,237,582,702,248, with the lowest BAK revenue forecast at $11,631,708,734,447, and the highest BAK revenue forecast at $12,843,456,670,049.

In 2027, BAK is forecast to generate $12,394,110,474,415 in revenue, with the lowest revenue forecast at $12,394,110,474,415 and the highest revenue forecast at $12,394,110,474,415.

What is BAK's forecast return on assets (ROA) for 2025-2027?

(NYSE: BAK) forecast ROA is 3.12%, which is higher than the forecast US Chemicals industry average of 2.35%.

What is BAK's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BAK price target, the average BAK price target is $5.00, with the highest BAK stock price forecast at $5.00 and the lowest BAK stock price forecast at $5.00.

The Wall Street analyst predicted that Braskem Sa's share price could reach $5.00 by Aug 27, 2026. The average Braskem Sa stock price prediction forecasts a potential upside of 46.63% from the current BAK share price of $3.41.

What is BAK's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: BAK) Braskem Sa's current Earnings Per Share (EPS) is -$4.93. On average, analysts forecast that BAK's EPS will be -$0.16 for 2025, with the lowest EPS forecast at -$0.23, and the highest EPS forecast at -$0.08. On average, analysts forecast that BAK's EPS will be $0.00 for 2026, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at $0.25. In 2027, BAK's EPS is forecast to hit $0.69 (min: $0.69, max: $0.69).

What is BAK's forecast return on equity (ROE) for 2025-2027?

(NYSE: BAK) forecast ROE is -66.26%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.